The Pharma Marketing Reset – Part Two
10 aug 2020
The Pharma Marketing Reset: Innovation
The radical change to deliver patient and customer-centric engagement
This 4-part white paper is written by SOPHIE STIEWE, a Graduate Marketing and Project Management Assistant at Uptake Strategies’. Sophie has a Master of Biochemistry in Molecular and Cellular Biochemistry from the University of Oxford. During her studies, she acquired a variety of practical experiences within the pharmaceutical industry via internships, competitions, and masterclasses at industry-leading companies. She is presently on a two-year fast track Graduate scheme and pursuing her interest in marketing by studying towards a CIM Diploma in Professional Marketing.
Part 2: Innovation
Innovation is an integral part of the pharma and biotech industry, driven by medicines and technology, yet studies suggest key stakeholders do not perceive the industry as innovative. To improve this perception, the pharma / biotech industry will need to drive innovation in areas beyond science and technology, such as marketing. In the second of our 4-part series ‘The Pharma Marketing Reset,’ we share and discuss insights from interviews conducted with senior industry professionals across different geographies and companies. These include:
1 – The current pharma / biotech marketing innovation enablers and barriers
2 – How these can be addressed to promote future innovation
Moreover, we provide suggestions as to how pharma brand teams could themselves introduce greater innovation: generating deeper insights and exploring innovative non-promotional programmes, multichannel marketing, and personalised digital channels.
If you would like to read Part 2 of this white paper contact Lauren.Pearson@uptakestrategies.com.